Juno Therapeutics

Clinical trials sponsored by Juno Therapeutics, explained in plain language.

Now part of Bristol-Myers Squibb Company BMY NYSE

A biotech developing CAR-T cell therapies, now part of Bristol-Myers Squibb.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Experimental cell therapy takes on Hard-to-Treat myeloma

Disease control Completed

This early-stage trial tested a new cell therapy called CC-95266 in 130 people with multiple myeloma that had come back or stopped responding to treatment. Participants also received chemotherapy drugs to prepare their bodies for the cell infusion. The main goals were to check sa…

Phase 1 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control

Last updated Jun 27, 2026 09:03 UTC

Juno Therapeutics

Experimental cell therapy takes on Hard-to-Treat myeloma